异动解读 | 生物技术公司Beam Therapeutics临床试验发生患者死亡,股价大跌17.69%

异动解读11-05

生物技术公司Beam Therapeutics(BEAM)11月5日股价大跌17.69%,主要原因是其基于CRISPR技术的细胞疗法BEAM-101早期临床试验中发生一名镰状细胞病患者死亡事故。

据报道,该名患者死于呼吸衰竭,很可能与为患者BEAM-101细胞输注做准备时使用的"busulfan"化疗调理药物有关。患者在输注BEAM-101治疗约四个月后不幸去世。

尽管这一事件极为不幸,但也凸显了当前临床试验方案和预处理方案仍需进一步改进以减少不良反应风险。公司目前已有8名患者接受了BEAM-101治疗。Beam Therapeutics第三季度净亏损9670万美元,同比去年略有增加。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1174325590?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-05 23:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174325590","market":"us","top_or_hot":-1,"title":"异动解读 | 生物技术公司Beam Therapeutics临床试验发生患者死亡,股价大跌17.69%","media":"异动解读","content":"<p>生物技术公司Beam Therapeutics(BEAM)11月5日股价大跌17.69%,主要原因是其基于CRISPR技术的细胞疗法BEAM-101早期临床试验中发生一名镰状细胞病患者死亡事故。</p>\n\n<p>据报道,该名患者死于呼吸衰竭,很可能与为患者BEAM-101细胞输注做准备时使用的\"busulfan\"化疗调理药物有关。患者在输注BEAM-101治疗约四个月后不幸去世。</p>\n\n<p>尽管这一事件极为不幸,但也凸显了当前临床试验方案和预处理方案仍需进一步改进以减少不良反应风险。公司目前已有8名患者接受了BEAM-101治疗。Beam Therapeutics第三季度净亏损9670万美元,同比去年略有增加。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 生物技术公司Beam Therapeutics临床试验发生患者死亡,股价大跌17.69%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 生物技术公司Beam Therapeutics临床试验发生患者死亡,股价大跌17.69%\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-05 23:42 北京时间&nbsp;&nbsp;&nbsp;<strong>异动解读</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>生物技术公司Beam Therapeutics(BEAM)11月5日股价大跌17.69%,主要原因是其基于CRISPR技术的细胞疗法BEAM-101早期临床试验中发生一名镰状细胞病患者死亡事故。\n据报道,该名患者死于呼吸衰竭,很可能与为患者BEAM-101细胞输注做准备时使用的\"busulfan\"化疗调理药物有关。患者在输注BEAM-101治疗约四个月后不幸去世。\n尽管这一事件极为不幸,但也凸显了...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BEAM","symbol_name":"Beam Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1174325590","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174325590","pubTimestamp":1730821353,"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"生物技术公司Beam Therapeutics(BEAM)11月5日股价大跌17.69%,主要原因是其基于CRISPR技术的细胞疗法BEAM-101早期临床试验中发生一名镰状细胞病患者死亡事故。\n\n据报道,该名患者死于呼吸衰竭,很可能与为患者BEAM-101细胞输注做准备时使用的\"busulfan\"化疗调理药物有关。患者在输注BEAM-101治疗约四个月后不幸去世。\n\n尽管这一事件极为不幸,但也凸显了当前临床试验方案和预处理方案仍需进一步改进以减少不良反应风险。公司目前已有8名患者接受了BEAM-101治疗。Beam Therapeutics第三季度净亏损9670万美元,同比去年略有增加。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BEAM":"Beam Therapeutics, Inc."},"translate_title":"Interpretation of changes: a patient died in a clinical trial of biotechnology company Beam Therapeutics, and the stock price fell 17.69%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BEAM":1},"content_text":"生物技术公司Beam Therapeutics(BEAM)11月5日股价大跌17.69%,主要原因是其基于CRISPR技术的细胞疗法BEAM-101早期临床试验中发生一名镰状细胞病患者死亡事故。\n据报道,该名患者死于呼吸衰竭,很可能与为患者BEAM-101细胞输注做准备时使用的\"busulfan\"化疗调理药物有关。患者在输注BEAM-101治疗约四个月后不幸去世。\n尽管这一事件极为不幸,但也凸显了当前临床试验方案和预处理方案仍需进一步改进以减少不良反应风险。公司目前已有8名患者接受了BEAM-101治疗。Beam Therapeutics第三季度净亏损9670万美元,同比去年略有增加。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174325590"}